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There are twenty-five published structures of Mycobacterium
tuberculosis anthranilate phosphoribosyltransferase (Mtb-AnPRT)
that use the same crystallization protocol. The structures include
protein complexed with natural and alternative substrates, pro-
tein:inhibitor complexes, and variants with mutations of sub-
strate-binding residues. Amongst these are varying space groups
(i.e. P21, C2, P21212, P212121). This article outlines experimental
details for 3 additional Mtb-AnPRT:inhibitor structures. For one
protein:inhibitor complex, two datasets are presented – one gen-
erated by crystallization of protein in the presence of the inhibitor
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G.L. Evans et al. / Data in Brief 15 (2017) 1019–10291020Automatic and manual processing of these datasets indicated the
same space group for both datasets and thus indicate that the
space group differences between structures of Mtb-AnPRT:ligand
complexes are not related to the method used to introduce the
ligand.
& 2017 The Authors. Published by Elsevier Inc. This is an open
access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).Specifications Tableubject area Proteomics and Biochemistry
ore specific sub-
ject areaStructural biologyype of data Tables, figures and X-ray diffraction images
ow data was
acquiredX-ray macromolecular crystallography;
Australian Synchrotron MX1 and MX2 beamlinesata format Unprocessed, processed, deposited with crystal packing analyzed.
xperimental
factorsProtein crystals soaked and co-crystallized with ligandsxperimental
featuresContrast of the different protein crystal packing associated with different inhi-
bitors and/or introduced by soaking or co-crystallization.
X-ray diffraction datasets for co-crystallization and soaked-in experiments with
the same inhibitor indicate space group changes are independent of method
used to introduce the inhibitor.ata source
locationData collected in Melbourne, Australia.ata accessibility The atomic coordinates and observed structure factors are available from Protein
Data Bank with accession numbers: 5BO2, 5BO3 and 5BNE.
The X-ray diffraction image files corresponding to datasets from two experi-
ments are hosted by Mendeley:
http://http://dx.doi.org/10.17632/2zrfgv34nb.1
http://http://dx.doi.org/10.17632/xgn5z8jnr7.1elated research
articleAnthranilate phosphoribosyltransferase: Binding determinants for 5′-phospho-
alpha-D-ribosyl-1′-pyrophosphate (PRPP) and the implications for inhibitor
design “in press”.
https://doi.org/10.1016/j.bbapap.2017.08.018Value of the data
 Mtb-AnPRT is a target of interest in developing novel anti-tuberculosis agents. This protein's
capacity to crystallize thus yield new protein:ligand complexes makes it of interest for structure-
based inhibitor design.
 Previously Mtb-AnPRT:ligand complexes have been found with different space groups (e.g. P21, C2,
P21212, and P212121), generated by using the same crystallization protocol.
 Mtb-AnPRT:inhibitor complex structures described herein have C2 and P21 space groups. These
structures were solved using X-ray diffraction datasets from protein:ligand crystals generated by
streak-seeded with wild-type P212121 crystal.
 For one inhibitor, X-ray diffraction datasets are presented for both co-crystallization and soaked
crystal experiments. Space group C2 occurred in both datasets and indicates the space group
G.L. Evans et al. / Data in Brief 15 (2017) 1019–1029 1021change between ligand-free and inhibitor-bound structures are independent of method used to
introduce the inhibitor.
 X-ray diffraction datasets utilizing different methods of ligand introduction and yielding equivalent
protein:ligand structures are typically not made available. These publically available datasets in the
context of multiple space groups observed for Mtb-AnPRT:ligand structures, and the analysis
presented herein, demonstrate that space group changes can be independent of co-crystallization
and soaking methods of ligand introduction. This has relevance to academic and industrial
researchers who are pursuing structure-based inhibitor design.1. Data
1.1. Overview
The experimental and data processing details for 3 new protein:ligand structures of Mycobacter-
ium tuberculosis anthranilate phosphoribosyl transferase (Mtb-AnPRT) are described herein (Table 1).
The protein structures are complexed with Mtb-AnPRT inhibitors characterized in [1] and annotated
as:
 8k (2-(2-carboxyphenylamino)-5-(5-phosphonopentyloxy)benzoic acid)
 8j (2-(2-carboxyphenylamino)-5-(4-phosphonobutoxy)benzoic acid)
 8i (2-(2-carboxyphenylamino)-5-(3-phosphonopropoxy)benzoic acid)
These structures were determined with protein crystallized in presence of imidazole-malate and
PEG4000. Crystallization drops seeded with crystal nuclei from a pre-existing Mtb-AnPRT crystal
generate better crystal morphology for Mtb-AnPRT [2]. All new structures presented herein were
generated by streak-seeding using wild-type P212121 crystals. Also presented are two X-ray diffrac-
tion datasets corresponding to protein crystals either soaked and co-crystallized with the same
inhibitor (Table 2).
Of the previously published structures of Mtb-AnPRT, 25 were determined from protein crystal-
lized using this protocol (Table 3). Most of these structures have a ligand bound (e.g. inhibitor or
substrate) and/or are protein variants with mutations in substrate-binding residues (Table 3).
Amongst both cohorts (Tables 1 and 3) several different space groups have been observed, including
P21, C2, P21212, P212121. Amongst the 28 structures referred to in this article (Tables 1 and 3), similar
unit cells correspond to each space group.
P212121 is the most common space group for macromolecular structures, and it has been proposed
that this is due to its capacity to accommodate repositioning, i.e. rotations or translations, within the
asymmetric unit, without loss of crystal contacts [3]. The structure of wild-type Mtb-AnPRT without
ligands (PDB ID: 3QR9) has previously been solved from protein crystallized in imidazole-malate and
PEG4000 in the space group P212121, with two monomers (A, B) in the asymmetric unit, a unit cell of
79×92×120 Å, and 57% solvent content [2].
Mtb-AnPRT is a homodimeric protein with an extended “S”-shape, with each subunit containing
two domains [4]. In the ligand-free structure, a single dimer (the biological assembly) is found in theTable 1
Summary of Mtb-AnPRT structures described herein.
PDB ID Ligand ID Solvent content Unit Cell Space group Resolution (Å) Chains PDB DOI
β (°) A (Å) B (Å) C (Å)
5BO2 8i 46% 111° 94 78 103 C2 2.00 A,B 10.2210/pdb5bo2/pdb
5BO3 8j 46% 111° 95 78 103 C2 1.75 A,B 10.2210/pdb5bo3/pdb
5BNE 8k 46% 91° 77 78 117 P21 2.15 A,B,C D 10.2210/pdb5bne/pdb
Table 2
Crystallization of complexes, along with space group and unit cell from data processing.
PDB ID Ligand(s) bound [Protein]
mg mL−1
Reservoir condition Cryoprotectant/Soak Notes Space
group
Unit cell
5BO2 8i : 3.0 0.2 M imidazole.
malate, pH 7.0, 9%
PEG4000
0.2 M imidazole.malate, pH
7.0, 15% PEG4000, 1 mM 8i
Streak seeded; soaked
crystal for 4 h;
C2 94×78×103 Å
2 day old crystal




Not applicable 8i : 3.0 0.2 M imidazole.
malate, pH 7.0, 11%
PEG4000, 1 mM 8i
0.2 M imidazole.malate, pH
7.0, 15% PEG4000, 1 mM 8i
Streak seeded; protein co-
crystallized with ligand;
C2 95×78×103 Å




5BO3 8j : 3.0 0.2 M imidazole.
malate, pH 7.0, 11%
PEG4000,
0.2 M imidazole.malate, pH
7.0, 15% PEG4000, 1 mM 8j
Streak seeded; soaked
crystal for 10 min;
C2 95×78×103 Å
2 day old crystal β¼111°
5BNE 8k : 3.1 0.2 M imidazole.
malate, pH 7.0, 15%
PEG4000, 1 mM 8k
No cryo used, because crys-
tallization condition con-
tained 15% PEG4000
Streak seeded; protein co-
crystallized with ligand;
P21 77×78×117 Å















Space groups, unit cells and other information for previously published Mtb-AnPRT structures crystallized in imidazole-malate and PEG4000.
PDB ID Ref Solvent content Unit Cell Space Group Resolution (Å) Chains Notes PDB DOI
β (°) A (Å) B (Å) C (Å)
3QS8 [2] 46% 90° 78 81 111 P21 2.00 A,B,C,D Co-crystal 10.2210/pdb3qs8/pdb
3UU1 [2] 45% 90° 78 111 80 P21 1.82 A,B,C,D Co-crystal 10.2210/pdb3uu1/pdb
3R6C [2] 44% 110° 94 78 100 C2 1.83 A,B Co-crystal 10.2210/pdb3r6c/pdb
4IJ1 [5] 45% 111 95 78 102 C2 1.79 A,B Co-crystal 10.2210/pdb4ij1/pdb
4X58 [6] 50% 111 95 78 101 C2 1.75 A,B Mutant 10.2210/pdb4x58/pdb
4X59 [6] 50% 112 95 78 102 C2 1.80 A,B Mutant 10.2210/pdb4x59/pdb
4X5A [6] 49% 112 94 78 102 C2 1.93 A,B Mutant 10.2210/pdb4x5a/pdb
4X5B [6] 45% 111 94 78 100 C2 2.47 A,B Mutant 10.2210/pdb4x5b/pdb
4X5C [6] 49% 111 94 78 101 C2 2.33 A,B Mutant 10.2210/pdb4x5c/pdb
4X5E [6] 50% 110 95 79 101 C2 1.77 A,B Mutant 10.2210/pdb4x5e/pdb
4GIU [5] 46% 90 111 81 79 P21212 1.67 A,B Co-crystal 10.2210/pdb4giu/pdb
4GKM [5] 46% 90 111 81 78 P21212 1.67 A,B Co-crystal 10.2210/pdb4gkm/pdb
3QR9 [2] 57% 90 79 92 120 P212121 1.87 A,B Ligand-free 10.2210/pdb3qr9/pdb
4M0R [5] 56% 90 79 92 120 P212121 1.96 A,B Co-crystal 10.2210/pdb4m0r/pdb
4N5V [7] 57% 90 80 93 121 P212121 1.90 A,B Soak 10.2210/pdb4n5v/pdb
4N8Q [7] 56% 90 80 91 120 P212121 2.08 A,B Soak 10.2210/pdb4n8q/pdb
4N93 [7] 57% 90 80 92 121 P212121 2.03 A,B Soak 10.2210/pdb4n93/pdb
4OWM [7] 60% 90 79 92 121 P212121 1.99 A,B Soak 10.2210/pdb4owm/pdb
4OWN [7] 60% 90 80 92 121 P212121 2.11 A,B Soak 10.2210/pdb4own/pdb
4OWO [7] 60% 90 79 92 121 P212121 1.99 A,B Soak 10.2210/pdb4owo/pdb
4OWQ [7] 61% 90 79 92 122 P212121 1.89 A,B Soak 10.2210/pdb4owq/pdb
4OWS [7] 60% 90 80 92 121 P212121 2.43 A,B Soak 10.2210/pdb4ows/pdb
4OWU [7] 60% 90 79 92 121 P212121 1.89 A,B Soak 10.2210/pdb4owu/pdb
4OWV [7] 60% 90 80 92 120 P212121 1.90 A,B Soak 10.2210/pdb4owv/pdb
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symmetry axis (NCS).
1.2. Data for protein complexes with inhibitors
The three protein:inhibitor complexes (PDB IDs: 5BO2, 5BO3, 5BNE) were solved in the absence of
metals and substrate. For these structures, the solvent content has decreased by ~ 10%, the unit cell
has changed (i.e. dimension(s) decreased by 10–20 Å), and the space group has changed to P21 or C2,
compared to the ligand-free wild-type structure.
In structures of AnPRT from other prokaryote species, domain movement is observed within
subunits due to substrate binding and results in compression of the homodimer by 10 Å (e.g. Dmax
(maximum distance) changes from 110 to 100 Å [8]). However, superposition of the subunits in the
new Mtb-AnPRT structures onto the subunits of the ligand-free structure indicates there are no large
changes (Table 4; [9]). Additionally, the longest dimension of the Mtb-AnPRT dimer is relatively
unchanged between the ligand-free protein structure and the protein:ligand complex structures
(Table 4; [10]). Thus, the changes in space group are not driven by domain movements within each
subunit.
The P21 structure (PDB ID: 5BNE) contains an inhibitor annotated as 8k, and is the third structure
of Mtb-AnPRT with this space group determined for protein crystallized in the imidazole-malate
condition. The increased components in this structure's asymmetric unit (chains A-D, vs. chains A and
B; Fig. 1A) means that the lower symmetry described by P21 can generate equivalent protein content
in a similarly-sized unit cell as is observed with structures defined by space groups P212121 or P21212.
The ß angle of 91° could be taken to suggest that the space group should be orthorhombic (e.g. P21212
or P212121). Both POINTLESS [11] and ZANUDA [12] indicated that P21 was the correct space group for
this dataset, however.
(A) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space
group P21, PDB ID: 5BNE (chain A, B, C and D in green, cyan, pink and yellow, respectively), onto that
of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; chain A and B in dark and light
grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b
plane in 3QR9 [2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the Mtb-AnPRT:
inhibitor structure in yellow and the ligand-free Mtb-AnPRT structure in dark grey. Arrows highlight
the reorientation of dimers relative to each other. (C) Superposition of the dimer (cartoon) from a
Mtb-AnPRT:inhibitor structure defined by space group C2, PDB ID: 5BO2 (marine blue) onto that of
the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; dark grey). In (D) superpositions in
panels B-C are combined.
Structural superposition of the dimers from Mtb-AnPRT:inhibitor structures (PDB ID: 5BNE and
5BO2) onto the dimer present in the P212121 ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2])
revealed a reorientation of the protein dimers relative to each other (Fig. 1B and C). The combinationTable 4







3qr9.pdb:A – 0.89 109
3qr9.pdb:B 0.89 –
5bo2.pdb:A 0.67 0.68 110
5bo2.pdb:B 0.66 0.73
5bo3.pdb:A 0.63 0.53 110
5bo3.pdb:B 0.62 0.73
5bne.pdb:A 0.57 0.53 109
5bne.pdb:B 0.46 0.74
5bne.pdb:C 0.46 0.92 109
5bne.pdb:D 0.55 0.60
a Root mean standard difference (RMSD) between the Calpha atoms
Fig. 1. Understanding changes in crystal packing in the Mtb-AnPRT structures with inhibitors. (A) Superposition of the dimer
(cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group P21, PDB ID: 5BNE (chain A, B, C and D in green, cyan,
pink and yellow, respectively), onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; chain A and B in
dark and light grey, respectively). The figure includes adjacent dimers (ribbons) in equivalent crystal layers (c-b plane in 3QR9
[2] and c-a plane in 5BNE). In (B) the superposition is re-colored with the Mtb-AnPRT:inhibitor structure in yellow and the
ligand-free Mtb-AnPRT structure in dark grey. Arrows highlight the reorientation of dimers relative to each other.
(C) Superposition of the dimer (cartoon) from a Mtb-AnPRT:inhibitor structure defined by space group C2, PDB ID: 5BO2
(marine blue) onto that of the ligand-free Mtb-AnPRT structure (PDB ID: 3QR9 [2]; P212121; dark grey). In (D) superpositions in
panels B-C are combined.
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intermediate position between the lattice observed for P212121 and C2 structures. We propose the
subunits that are related by crystallographic symmetry elements in the P212121 structures are related
by pseudosymmetry elements in the P21 structure. Pseudosymmetry occurs where a non-crystal-
lographic symmetry element within the asymmetric unit is close to a crystallographic symmetry
operators [13]. Thus, the P21 space group has been correctly assigned, even though the unit cell has a
β of approximately 90 °.
The generation of the protein: inhibitor structures, involved experiments, with all three inhibitors,
using both co-crystallization and soaking-in methods. The structures deposited on the PDB corre-
spond to those where the clearest density was observed for the inhibitor (i.e. modelled with full
occupancy; Fig. 2). In Table 5 there are data statistics corresponding to Mtb-AnPRT co-crystallized
with inhibitor 8i. In Table 6 are data statistics corresponding to inhibitor 8i soaked into a wild-type
ligand-free Mtb-APRT crystal. In both cases, with no manual intervention, the datasets processed in
XDS [14] and AIMLESS [11] as space group C2. Thus, in this study, there no correlation was found
between space group type and the method by which the ligand was introduced (i.e. soaking vs. co-
crystallization).
Fig. 2. Omit and fitted map for inhibitors bound in Mtb-AnPRT structures. The Fo-Fc map calculated (green, contoured at 3 σ)
prior to the addition of ligands to the model for A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2Fo-
Fc map calculated (blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j
(green) and F) 8i (pink).
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2.1. Materials
Unless otherwise stated, all chemicals were obtained from Sigma-Aldrich, Scharlau, or Pure Sci-
ence. The purification of Mtb-AnPRT, as well as the synthesis and biochemical characterization of its
inhibitors annotated as 8i, 8j and 8k (Table 2), are outlined in the article entitled “Anthranilate
phosphoribosyltransferase: Binding determinants for 5′-phospho-alpha-D-ribosyl-1′-pyrophosphate
(PRPP) and the implications for inhibitor design” [1].
Table 6
Data and refinement statistics for AnPRT complexes with inhibitors.
Data collection
AnPRT complexed with 8i 8j 8k
PDB code 5BO2 5BO3 5BNE
Space group C2 C2 P21
Cell dimensions
a, b, c (Å) 94.5, 78.0, 102.9 95.0, 78.1, 102.6 77.3, 78.4, 117.2
β (deg) 111.0 111.1 90.7
Unique reflectionsa 47170 (3415) 68993 (3669) 75079 (4387)
Resolution range (Å)a 47-2.00 (2.05-2.00) 48-1.75 (1.78-1.75) 47-2.15 (2.19-2.15)
Rmerge
a 0.121 (0.856) 0.121 (1.762) 0.111 (0.711)
Rp.i.m.
a 0.076 (0.564) 0.046 (0.688) 0.073 (0.477)
Mean I/σ(I)a 8.5 (1.5) 13.3 (1.2) 6.9 (1.5)
CC1/2a 0.993 (0.564) 0.998 (0.465) 0.993 (0.502)
Completeness (%)a 99.8 (97.7) 97.8 (93.7) 98.4 (77.3)
Redundancya 3.4 (3.3) 7.8 (7.4) 3.0 (2.9)
Wilson B factor 15.1 16.3 21.4
Refinement
Atoms, B factor (Å2)b
Protein 4788, 25.8 4746, 24.6 9280, 29.0
Solvent 352, 29.7 402, 29.2 353, 29.5
Ligands 79, 33.2 66, 26.6 107, 30.6
Rwork/Rfree (%/%)a,c 0.192/0.232 0.206/0.240 0.207/0.235
(0.276/0.324) (0.319/0.336) (0.284/0.332)
Ramachandran outliers (%) 0.31 0.16 0.31
R.m.s.d. of
Bond lengths (Å)d 0.003 0.005 0.003
Bond angles (°)d 0.774 0.899 0.745
a Outer resolution shell is shown in parentheses.
b The average atomic temperature factor.
c Rwork¼(|Fobs| - |Fcalc|)/|Fobs| and Rfree¼∑T (|Fobs| - |Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections
randomly chosen and set aside before refinement.
d RMSD from ideal geometry values from Engh and Huber [15].
Table 5
Statistics for dataset of Mtb-AnPRT co-crystallized with inhibitor 8i.
Data collection
AnPRT complexed with 8i
Space group C2
Cell dimensions
a, b, c (Å) 94.6, 78.1, 102.8
β (deg) 110.9
Unique reflectionsa 387946 (24179)





Mean I/σ(I)a 9.9 (1.5)
CC1/2a 0.997 (0.679)
Completeness (%)a 99.6 (94.0)
Redundancya 7.6 (7.1)
Wilson B factor 20.5
b The average atomic temperature factor. c Rwork¼(|Fobs| - |Fcalc|)/|Fobs| and Rfree¼∑T (|Fobs| - |
Fcalc|)/∑T |Fobs|, where T is a test dataset of 5% of the total reflections randomly chosen and
set aside before refinement. d RMSD from ideal geometry values from Engh and Huber
(1991) [15].
a Outer resolution shell is shown in parentheses.
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Crystals of Mtb-AnPRT were obtained in hanging drops of 1–2 μL protein solution (3.0–
3.1 mg mL−1 in final storage buffer) with the equivalent amount of reservoir solution in a fine screen
of 0.2 M imidazole-malate pH 7.0–8.5, 5–15% polyethylene glycol (PEG) 4000, as previously reported
[2]. Complexes were prepared either by co-crystallization or by soaking with ligands (details in
Table 2). The crystallization drops were seeded from previously formed crystals of Mtb-AnPRT, by
streak seeding using a cat whisker. Data collection occurred within a few days after crystallization. In
preparation for data collection, crystals were typically soaked in a reservoir solution containing
cryoprotectant 15% PEG4000 and appropriate ligands (details in Table 2), before being flash-cooled in
liquid nitrogen.2.3. Data collection, structure solution and refinement
Data were collected at the Australian Synchrotron, Beamlines MX1 and MX2 at 110 K. The crystals
of the Mtb-AnPRT complexes diffracted to a maximum resolution that varied between 1.75 and 2.15 Å.
X-ray diffraction spots were indexed and integrated with XDS [14] and scaled with AIMLESS [11]. The
high resolution cut-off was determined based on a correlation coefficient (CC1/2) [16] exceeding 0.5,
with mean I/σ between 1 and 1.5, and a Rp.i.m. of 0.7 or less, as calculated by AIMLESS [11]. Rp.i.m. is
defined as ∑hkl [1/(n−1)]×Rmerge, with Rmerge defined as ∑hkl|I(hkl)-o I(hkl)4 |/∑hklo I(hkl)4 ,
where o I(hkl)4 is the mean of symmetry-equivalent reflections of I(hkl) [17]. Data and refinement
statistics are given in Tables 5 and 6.
Mtb-AnPRT (chain A of 3QR9 [2]), without solvent or ligands, and with loops I and II removed, was
used as the search model for structure determination by molecular replacement using Phaser [18].
Refinement and model building was performed with COOT [19], Refmac5 [20], and PHENIX [21]. After
positioning waters, omit maps were examined (Fig. 2) and ligands placed, with subsequent refine-
ment including restraints for the ligands generated by phenix.elbow [21]. Restraints on protein bond
lengths and angles were based on the ideal values of Engh and Huber [15] and model quality was
assessed using MolProbity [22]. Figures illustrating structural details were prepared using PyMOL.
The Fo-Fc map calculated (green, contoured at 3 σ) prior to the addition of ligands to the model for
A) 8k, B) 8j and C) 8i (PDB entries 5BNE, 5BO3 and 5BO2, respectively). The 2Fo-Fc map calculated
(blue, contoured at 1 σ) after final refinement, with model including the ligands for D) 8k (black), E) 8j
(green) and F) 8i (pink).Acknowledgements
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